Plasma biomarkers of Alzheimer’s neuropathy linked to dementia risk
Aug 01, 2024
Significant associations were seen for all Alzheimer’s disease plasma biomarkers in late life with late-life dementia.
Timing of CSF biomarker divergence for Alzheimer’s disease, normal cognition varies
Feb 21, 2024
Estimated times of divergence of cerebrospinal fluid biomarkers vary from 18 years for Aβ42 to six years for cognitive decline.
Panel of 48 CSF proteins complements existing Alzheimer’s biomarkers
Sep 07, 2023
The CSF 48 panel plus existing biomarkers significantly improved the diagnostic performance for the outcomes studied.
Composite inflammatory biomarker linked to dementia risk
Jul 21, 2023
Small but significant associations were seen between elevated biomarker levels and worsened cognitive performance.
Finger prick, venous blood can ID key Alzheimer’s disease biomarkers
Jul 20, 2023
Capillary and venous dry blood spot can identify glial fibrillary acidic protein, neurofilament light and phosphorylated tau.
Plasma biomarkers identified for detecting presymptomatic Alzheimer’s disease
Jan 13, 2023
Plasma P-tau181, NfL and GFAP concentrations were higher in mutation carriers versus noncarriers of autosomal dominant Alzheimer’s disease.
Lecanemab reduced markers of amyloid in early Alzheimer’s disease
Dec 01, 2022
Moderately less decline was seen in cognition and function at 18 months with lecanemab versus placebo.
Changes in Alzheimer’s biomarkers tied to withdrawal of PAP for OSA
Jul 08, 2022
An increase in neurofilament light and a decrease in Aβ40 were associated with withdrawal of positive airway pressure for obstructive sleep apnea.
FDA OKs marketing of new test to help diagnose Alzheimer disease
May 06, 2022
The test is indicated for patients 55 years and older who present with cognitive impairment and are being evaluated for Alzheimer’s disease and cognitive decline.
DMARDs not linked to Alzheimer’s risk for seniors with RA
Apr 12, 2022
No reduction in the risk for Alzheimer’s disease and related dementia was seen with treatment with tofacitinib, tocilizumab or tumor necrosis factor inhibitors versus abatacept.